Marinus Pharmaceuticals, Inc.
Method of treatment using nanoparticulate ganaxolone formulations

Abstract:

In certain embodiments, the invention is directed to composition comprising stable particles comprising ganaxolone, wherein the volume weighted median diameter (D50) of the particles is from about 50 nm to about 500 nm.